title: Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model.
abstract: BACKGROUND
  Intermittent androgen suppression (IAS) has been proposed as a method of delaying the onset of androgen-independent growth in prostate cancer. While several pilot studies have demonstrated the feasibility of such a treatment, no study to date has defined the effect of IAS on survival.
  
  
  METHODS
  We developed an IAS protocol for mice bearing the LuCaP 23.12 human prostate cancer xenograft, with each cycle consisting of 1 week of androgen replacement with a testosterone pellet followed by 3 weeks of androgen withdrawal. Mice that responded to castration with a 40% or greater decrease in serum prostate-specific antigen (PSA) were randomized to treatment with either continuous androgen suppression (CAS) or IAS. Serum PSA, tumor volume, and overall survival were monitored.
  
  
  RESULTS
  A total of 75 mice met the randomization criteria. There was no significant difference of survival between animals treated with CAS or IAS (185 vs. 239 days, P = 0.1835). Serum PSA showed evidence of cycling with hormonal manipulation. No cycling was noted in tumor volume.
  
  
  CONCLUSIONS
  IAS is not associated with a decrease in survival compared to CAS, yet in patients may offer quality-of-life improvements. Further studies of IAS in the setting of Institutional Review Board (IRB) approved clinical trials should be encouraged. Prostate 43:63-70, 2000. Published 2000 Wiley-Liss, Inc.
authors.affiliation: Department of Urology, University of Washington, Seattle, Washington 98195, USA.
authors.forename: K R
authors.initials: KR
authors.lastname: Buhler
authors.forename: R A
authors.initials: RA
authors.lastname: Santucci
authors.forename: R A
authors.initials: RA
authors.lastname: Royai
authors.forename: S C
authors.initials: SC
authors.lastname: Whitney
authors.forename: R L
authors.initials: RL
authors.lastname: Vessella
authors.forename: P H
authors.initials: PH
authors.lastname: Lange
authors.forename: W J
authors.initials: WJ
authors.lastname: Ellis
mesh_terms: D000818:Animals; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011897:Random Allocation; D013739:Testosterone / Q000008:administration & dosage* / Q000627:therapeutic use; D014183:Transplantation, Heterologous
chemical_list: D013739:Testosterone; D017430:Prostate-Specific Antigen